Industry
Cellestis
Total Trials
3
Recruiting
0
Active
0
Completed
2
Success Rate
66.7%-20% vs avg
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 70/100
Failure Rate
33.3%
1 terminated/withdrawn out of 3 trials
Success Rate
66.7%
-19.8% vs industry average
Late-Stage Pipeline
33%
1 trials in Phase 3/4
Results Transparency
0%
0 of 2 completed trials have results
Key Signals
Enrollment Performance
Analytics
N/A
1(50.0%)
Phase 4
1(50.0%)
2Total
N/A(1)
Phase 4(1)
Activity Timeline
Global Presence
Loading network data...
Clinical Trials (3)
Showing 3 of 3 trials
NCT00424684Not ApplicableWithdrawn
Comparison of the Quantiferon®-TB GOLD (in Tube) Assay With Tuberculin Skin Testing for Detecting Latent Tuberculosis Infection in Patients With Chronic Liver Disease Being Evaluated for or Awaiting Liver Transplantation
Role: collaborator
NCT01223534Phase 4Completed
QuantiFERON®-TB Gold In-Tube for the Diagnosis of Tuberculosis Infection in Contact Tracing Study.
Role: collaborator
NCT00168259Completed
Evaluation of Interferon-gamma Responses to HCMV Infection in HIV Positive Individuals
Role: collaborator
All 3 trials loaded